Clinical trials: MRD
NSCLC Stage IIIA/B, NSCLC Stage II
Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective
This research focuses on exploring biomarkers for the application of PD - 1/PD - L1 immune checkpoint inhibitors in the perioperative immunotherapy of lung cancer.
- Trial name
- NCT06856798
- Volunteers
- 120 people
- Sponsor
- Ziming Li
Myeloma
Non-invasive MRD Assessment in Multiple Myeloma
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously…
- Trial name
- NIRVANA (NCT05625971)
- Testing
- MRD Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rajshekhar Chakraborty, MD
ALL, Recurrent, Adult
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT.
- Trial name
- NCT03109093
- Testing
- Blinatumomab
- Where
- 22 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Goethe University
Gastric Cancer
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and…
- Trial name
- MRD-GC (NCT06893133)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University
Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.
- Trial name
- NCT07264010
- Testing
- Sorafenib (SORA), Venetoclax (VEN)
- Volunteers
- 87 people
- Sponsor
- Nanfang Hospital, Southern Medical University
MRD, Prostate Cancer
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
- Conditions
- MRD, Prostate Cancer, mHSPC
- Trial name
- NCT07112612
- Volunteers
- 50 people
- Sponsor
- Anhui Medical University
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
Colon Cancer, Resected Stage
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for…
- Trial name
- NCT05040568
- Testing
- Cetuximab, Expanded CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Ptosis, Eyelid
Evaluation of Intraoperative Lagophthalmos Formula
This is a prospective non-randomized study to evaluate the recent intraoperative lagophthalmos formula method for levator resection in determining postoperative eyelid height in congenital ptosis on Egyptian children.
- Trial name
- NCT04291625
- Testing
- Levator muscle resection
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Menoufia University
Relapsed / Refractory Multiple Myeloma
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
This study is testing whether a lower dose of belantamab mafodotin used together with pomalidomide and dexamethasone can provide similar effectiveness with fewer side effects compared with the standard dose in patients with…
- Trial name
- REBEL (NCT07748689)
- Testing
- Belantamab Mafodotin, Pomalidomide, Dexamethasone
- Volunteers
- 228 people
- Sponsor
- Polish Myeloma Consortium
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA-BLIN-01/PET069014 (BLIN-01)
The PETHEMA Spanish group treats patients with high-risk Philadelphia chromosome-negative ALL, aged 18 to 55 years, based on the MRD clearance as assessed by flow cytometry at a centralised evaluation centre.
- Trial name
- NCT03523429
- Testing
- blinatumomab
- Where
- 12 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL).
- Trial name
- NCT03913559
- Testing
- Inotuzumab ozogamicin, Methotrexate, Hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- St. Jude Children's Research Hospital
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
This phase II trial studies how well ABL001 works in treating patients with chronic myeloid leukemia who are on therapy with tyrosine kinase inhibitor.
- Trial name
- NCT04216563
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
MCLA-117 in Acute Myelogenous Leukemia
This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.
- Trial name
- NCT03038230
- Testing
- MCLA-117 bispecific antibody
- Where
- 9 sites in United States, Belgium and 3 more
- Volunteers
- 80 people
- Sponsor
- Merus B.V.
Lung Cancer
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell…
- Trial name
- APPROACH (NCT04841811)
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Guangdong Association of Clinical Trials
Colorectal Cancer, Stage III Colon Cancer
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Conditions
- Colorectal Cancer, Stage III Colon Cancer, Minimal Residual Disease, Liquid Biopsy
- Trial name
- NCT06287814
- Testing
- Blood sample/lliquid biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Montpellier
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
This investigator-initiated, prospective, single-arm, open-label, single-center clinical study aims to evaluate the efficacy and safety of Inaticabtagene autoleucel (Inati-cel;CNCT19)CD19 CAR-T theraphy in adults B-ALL that are…
- Trial name
- NCT06718244
- Testing
- single dose of Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR)
Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)
The present study aims at studying how safe and tolerable a new therapy for patients with Acute Lymphoblastic Leukemia (ALL) is.
- Conditions
- Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD)
- Trial name
- NCT02185781
- Testing
- Autologous NK cells infusions
- Where
- 6 sites in Italy
- Volunteers
- 6 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Non Small Cell Lung Cancer
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC
- Trial name
- NCT07661173
- Testing
- Firmonertinib, Firmonertinib/pemetrexed/Carboplatin, Firmonertinib/pemetrexed/Carboplatin/Bevacizumab
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Anhui Provincial Cancer Hospital